Mga Batayang Estadistika
| LEI | 529900QRZSA95XUDBE25 |
| CIK | 1138776 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Medgenics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 14, 2020 |
MDGN / Medgenics, Inc. 15-12B - - 15-12B 15-12B 1 tm207636-11512b.htm 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-35112 Aevi Genomic Medicine, LLC (Ex |
|
| February 14, 2020 |
MDGN / Medgenics, Inc. / Baker Brothers Advisors LP - SCHEDULE 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aevi Genomic Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00835P105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 12, 2020 |
As filed with the Securities and Exchange Commission on February 12, 2020 As filed with the Securities and Exchange Commission on February 12, 2020 Registration No. |
|
| February 12, 2020 |
GNMC / Aevi Genomic Medicine, Inc. RW - - RW February 12, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D. |
|
| February 12, 2020 |
As filed with the Securities and Exchange Commission on February 12, 2020 As filed with the Securities and Exchange Commission on February 12, 2020 Registration No. |
|
| February 12, 2020 |
GNMC / Aevi Genomic Medicine, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 12, 2020 Registration No. |
|
| February 12, 2020 |
As filed with the Securities and Exchange Commission on February 12, 2020 S-8 POS 1 tm207641-3s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on February 12, 2020 Registration No. 333-182992 Registration No. 333-188709 Registration No. 333-191733 Registration No. 333-195165 Registration No. 333-210737 Registration No. 333-219788 Registration No. 333-226134 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMEND |
|
| February 12, 2020 |
GNMC / Aevi Genomic Medicine, Inc. POS AM - - POS AM As filed with the Securities and Exchange Commission on February 12, 2020 Registration No. |
|
| February 12, 2020 |
As filed with the Securities and Exchange Commission on February 12, 2020 As filed with the Securities and Exchange Commission on February 12, 2020 Registration No. |
|
| February 12, 2020 |
As filed with the Securities and Exchange Commission on February 12, 2020 POS AM 1 tm207624-1posam.htm POS AM As filed with the Securities and Exchange Commission on February 12, 2020 Registration No. 333-182740 Registration No. 333-208586 Registration No. 333-221950 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT NO. 333-182740 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATI |
|
| February 12, 2020 |
As filed with the Securities and Exchange Commission on February 12, 2020 As filed with the Securities and Exchange Commission on February 12, 2020 Registration No. |
|
| February 12, 2020 |
As filed with the Securities and Exchange Commission on February 12, 2020 S-8 POS 1 tm207641-2s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on February 12, 2020 Registration No. 333-182992 Registration No. 333-188709 Registration No. 333-191733 Registration No. 333-195165 Registration No. 333-210737 Registration No. 333-219788 Registration No. 333-226134 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMEND |
|
| February 12, 2020 |
As filed with the Securities and Exchange Commission on February 12, 2020 As filed with the Securities and Exchange Commission on February 12, 2020 Registration No. |
|
| February 7, 2020 |
MDGN / Medgenics, Inc. / ASTRAZENECA PLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 AEVI GENOMIC MEDICINE, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 00835P105 (CUSIP Number) AstraZeneca PLC Attn: Adrian Kemp 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom +44 20 3749 5000 (Name |
|
| February 3, 2020 |
Exhibit 10.1 OPTION TERMINATION AGREEMENT THIS OPTION TERMINATION AGREEMENT (this “Agreement”) is made as of January 30, 2020, by and between the undersigned (the “Option Holder”) and Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”). RECITALS A. The Company granted to the Option Holder options to acquire shares of the Company’s common stock, par value $0.0001 per share, pursuant |
|
| February 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 3, 2020 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organiz |
|
| February 3, 2020 |
Limited Liability Company Agreement of Second Genie Merger Sub, LLC Exhibit 3.2 LIMITED LIABILITY COMPANY AGREEMENT OF SECOND GENIE MERGER SUB, LLC THIS LIMITED LIABILITY COMPANY AGREEMENT OF SECOND GENIE MERGER SUB, LLC, a Delaware limited liability company (the “Company”), is hereby adopted and approved by its sole member, Cerecor Inc., a Delaware corporation (the “Member”), and confirmed and agreed to by the Company effective as of November 27, 2019. W I T N E |
|
| February 3, 2020 |
Exhibit 10.2 OPTION TERMINATION AGREEMENT THIS OPTION TERMINATION AGREEMENT (this “Agreement”) is made as of January 30, 2020, by and between the undersigned (the “Option Holder”) and Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”). RECITALS A. The Company granted to the Option Holder options to acquire shares of the Company’s common stock, par value $0.0001 per share, pursuant |
|
| February 3, 2020 |
Certificate of Formation of Second Genie Merger Sub, LLC. Exhibit 3.1 CERTIFICATE OF FORMATION OF SECOND GENIE MERGER SUB, LLC This Certificate of Formation of Second Genie Merger Sub, LLC, dated as of the 27th day of November, 2019, is being duly executed and filed by David P. Creekman, as an authorized person, to form a limited liability company under the Delaware Limited Liability Company Act (6 Del. C. § 18-101, et seq.). FIRST. The name of the limit |
|
| January 6, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 31, 2019 |
GNMC / Aevi Genomic Medicine, Inc. DEFM14A - - DEFM14A Use these links to rapidly review the document TABLE OF CONTENTS AEVI GENOMIC MEDICINE, INC. |
|
| December 23, 2019 |
Exhibit 99.1 Establishing a leading, rare disease - focused biopharmaceutical company to deliver impactful new medicines to patients Driven by Science Inspired by Hope December | 2019 2 | Confidential Forward - Looking Statements This presentation may include forward - looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward - looking statements are stateme |
|
| December 23, 2019 |
CERC / Cerecor Inc. 425 - Merger Prospectus - 8-K 425 1 december2019investorpresen.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 23, 2019 CERECOR INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0 |
|
| December 23, 2019 |
Exhibit 99.1 Establishing a leading, rare disease - focused biopharmaceutical company to deliver impactful new medicines to patients Driven by Science Inspired by Hope December | 2019 2 | Confidential Forward - Looking Statements This presentation may include forward - looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward - looking statements are stateme |
|
| December 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organi |
|
| December 23, 2019 |
GNMC / Aevi Genomic Medicine, Inc. 425 - Merger Prospectus - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organi |
|
| December 23, 2019 |
cerecoraevimergerdeck122 Exhibit 99.1 Driven by Science Inspired by Hope Establishing a leading, rare disease-focused biopharmaceutical company to deliver impactful new medicines to patients December | 2019 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are stateme |
|
| December 11, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incor |
|
| December 11, 2019 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION By and Among CERECOR INC. GENIE MERGER SUB, INC. SECOND GENIE MERGER SUB, LLC and AEVI GENOMIC MEDICINE, INC. Dated as of December 5, 2019 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This Agreement and Plan of Merger and Reorganization (this “Agreement”), is entered into as of December 5, 2019, by and among Aevi Genomic Medicine, Inc. |
|
| December 11, 2019 |
GNMC / Aevi Genomic Medicine, Inc. 425 - Merger Prospectus - FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incor |
|
| December 11, 2019 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER AND REORGANIZATION By and Among CERECOR INC. GENIE MERGER SUB, INC. SECOND GENIE MERGER SUB, LLC and AEVI GENOMIC MEDICINE, INC. Dated as of December 5, 2019 Execution Version AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This Agreement and Plan of Merger and Reorganization (this “Agreement”), is entered into as of December 5, 2019, by a |
|
| December 11, 2019 |
CERC / Cerecor Inc. 425 - Merger Prospectus - 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 5, 2019 CERECOR INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37590 45-0705648 (Co |
|
| December 11, 2019 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER AND REORGANIZATION By and Among CERECOR INC. GENIE MERGER SUB, INC. SECOND GENIE MERGER SUB, LLC and AEVI GENOMIC MEDICINE, INC. Dated as of December 5, 2019 Execution Version AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This Agreement and Plan of Merger and Reorganization (this “Agreement”), is entered into as of December 5, 2019, by a |
|
| December 10, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organiz |
|
| December 10, 2019 |
Form of Warrant Amendment Agreement of Aevi Genomic Medicine, Inc. dated December 5, 2019 Exhibit 4.1 amendment Agreement of Warrants to purchase Common Stock This amendment AGREEMENT of Warrants to Purchase common Stock (this “Agreement”) is made as of December 5, 2019, by and between Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”) and the undersigned holders (each a “Holder” and collectively the “Holders”). The Company and the Holders are sometimes referred to her |
|
| December 10, 2019 |
Form of Warrant Amendment Agreement of Aevi Genomic Medicine, Inc. dated December 5, 2019 Exhibit 4.1 amendment Agreement of Warrants to purchase Common Stock This amendment AGREEMENT of Warrants to Purchase common Stock (this “Agreement”) is made as of December 5, 2019, by and between Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”) and the undersigned holders (each a “Holder” and collectively the “Holders”). The Company and the Holders are sometimes referred to her |
|
| December 10, 2019 |
GNMC / Aevi Genomic Medicine, Inc. 425 - Merger Prospectus - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organiz |
|
| December 6, 2019 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 5, 2019 |
Form of Voting Agreement of Aevi Genomic Medicine, Inc. dated December 5, 2019 Exhibit 10.1 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of December 5, 2019, by and between Cerecor, Inc., a Delaware corporation (“Cerecor”), Aevi Genomic Medicine, Inc., a Delaware corporation (“Aevi”), and the undersigned holders (each a “Holder” and collectively the “Holders”). Cerecor, Aevi and the Holders are sometimes referred to herein collectivel |
|
| December 5, 2019 |
CERC / Cerecor Inc. 425 - Merger Prospectus - 8-K 425 1 a8-ksigningofaevimergeragr.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 5, 2019 CERECOR INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 00 |
|
| December 5, 2019 |
Exhibit 10.2 PROMISSORY NOTE $5,000,000 December 5, 2019 FOR VALUE RECEIVED, Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”) (“Maker”) promises to pay to the order of Cerecor Inc., a Delaware corporation (“Payee”), at the address set forth in paragraph 9 below, the lesser of (i) the principal sum of Five Million Dollars ($5,000,000) (the “Maximum Amount”), or (ii) the unpaid pr |
|
| December 5, 2019 |
Exhibit 99.1 Cerecor to Acquire Aevi Genomic Medicine -Expands Clinical-stage Pipeline, Further Positioning Cerecor as a leader in Rare and Orphan Diseases -Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical Officer -Strategic Alternatives Being Explored for Neurological Assets and Millipred® Rockville, MD, December 5, 2019 — Cerecor Inc. (NASDAQ: CERC), a biop |
|
| December 5, 2019 |
Form of Voting Agreement of Aevi Genomic Medicine, Inc. dated December 5, 2019 Exhibit 10.1 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of December 5, 2019, by and between Cerecor, Inc., a Delaware corporation (“Cerecor”), Aevi Genomic Medicine, Inc., a Delaware corporation (“Aevi”), and the undersigned holders (each a “Holder” and collectively the “Holders”). Cerecor, Aevi and the Holders are sometimes referred to herein collectivel |
|
| December 5, 2019 |
Form of Contingent Value Rights Agreement by and between Cerecor Inc. and Rights Agent. Exhibit 10.1 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT This Contingent Value Rights Agreement, dated as of (this “Agreement”), is entered into by and between Cerecor Inc., a Delaware corporation (“Parent”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, as “Rights Agent”. RECITALS WHEREAS, Parent, Genie Merger Sub, Inc., a Delaware corporation (“Merge |
|
| December 5, 2019 |
GNMC / Aevi Genomic Medicine, Inc. 425 - Merger Prospectus - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organiz |
|
| December 5, 2019 |
Cerecor to Acquire Aevi Genomic Medicine Exhibit 99.1 Cerecor to Acquire Aevi Genomic Medicine Philadelphia, PA– December 5, 2019 – Aevi Genomic Medicine, Inc. (“Aevi”) (Nasdaq: GNMX) today announced that it entered into a definitive merger agreement with Cerecor, Inc. (“Cerecor”) (Nasdaq: CERC) pursuant to which Aevi will merge with a wholly owned subsidiary of Cerecor in an all-stock transaction (the “Merger”) valued at approximately $ |
|
| December 5, 2019 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER AND REORGANIZATION By and Among CERECOR INC. GENIE MERGER SUB, INC. SECOND GENIE MERGER SUB, LLC and AEVI GENOMIC MEDICINE, INC. Dated as of December 5, 2019 Execution Version AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This Agreement and Plan of Merger and Reorganization (this “Agreement”), is entered into as of December 5, 2019, by a |
|
| December 5, 2019 |
Exhibit 10.3 PROMISSORY NOTE $5,000,000 December 5, 2019 FOR VALUE RECEIVED, Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”) (“Maker”) promises to pay to the order of Cerecor Inc., a Delaware corporation (“Payee”), at the address set forth in paragraph 9 below, the lesser of (i) the principal sum of Five Million Dollars ($5,000,000) (the “Maximum Amount”), or (ii) the unpaid pr |
|
| December 5, 2019 |
Exhibit 10.4 PROMISSORY NOTE $5,000,000 December 5, 2019 FOR VALUE RECEIVED, Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”) (“Maker”) promises to pay to the order of Cerecor Inc., a Delaware corporation (“Payee”), at the address set forth in paragraph 9 below, the lesser of (i) the principal sum of Five Million Dollars ($5,000,000) (the “Maximum Amount”), or (ii) the unpaid pr |
|
| December 5, 2019 |
Exhibit 10.2 VOTING AGREEMENT THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of December 5, 2019, by and between Cerecor, Inc., a Delaware corporation (“Cerecor”), Aevi Genomic Medicine, Inc., a Delaware corporation (“Aevi”), and the undersigned holders (each a “Holder” and collectively the “Holders”). Cerecor, Aevi and the Holders are sometimes referred to herein collectivel |
|
| December 5, 2019 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER AND REORGANIZATION By and Among CERECOR INC. GENIE MERGER SUB, INC. SECOND GENIE MERGER SUB, LLC and AEVI GENOMIC MEDICINE, INC. Dated as of December 5, 2019 Execution Version AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This Agreement and Plan of Merger and Reorganization (this “Agreement”), is entered into as of December 5, 2019, by a |
|
| December 5, 2019 |
EX-10.2 4 tm1924560d1ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 PROMISSORY NOTE $5,000,000 December 5, 2019 FOR VALUE RECEIVED, Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”) (“Maker”) promises to pay to the order of Cerecor Inc., a Delaware corporation (“Payee”), at the address set forth in paragraph 9 below, the lesser of (i) the principal sum of Five Million Dollars ($5,000,000) |
|
| December 5, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organiz |
|
| December 5, 2019 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION By and Among CERECOR INC. GENIE MERGER SUB, INC. SECOND GENIE MERGER SUB, LLC and AEVI GENOMIC MEDICINE, INC. Dated as of December 5, 2019 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This Agreement and Plan of Merger and Reorganization (this “Agreement”), is entered into as of December 5, 2019, by and among Aevi Genomic Medicine, Inc. |
|
| December 5, 2019 |
Cerecor to Acquire Aevi Genomic Medicine Exhibit 99.1 Cerecor to Acquire Aevi Genomic Medicine Philadelphia, PA– December 5, 2019 – Aevi Genomic Medicine, Inc. (“Aevi”) (Nasdaq: GNMX) today announced that it entered into a definitive merger agreement with Cerecor, Inc. (“Cerecor”) (Nasdaq: CERC) pursuant to which Aevi will merge with a wholly owned subsidiary of Cerecor in an all-stock transaction (the “Merger”) valued at approximately $ |
|
| December 5, 2019 |
Exhibit 10.5 BACKSTOP AGREEMENT This BACKSTOP AGREEMENT (this “Agreement”), dated as of December 5, 2019, is entered into by and between Cerecor Inc., a Delaware corporation with offices located at 540 Gaither Road, Suite 400, Rockville, Maryland 20850 (the ”Company”), and Armistice Capital Master Fund Ltd. (the “Backstop Investor”). RECITALS WHEREAS, the Company desires to enter into an Agreement |
|
| December 5, 2019 |
Exhibit 10.3 PROMISSORY NOTE $5,000,000 December 5, 2019 FOR VALUE RECEIVED, Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”) (“Maker”) promises to pay to the order of Cerecor Inc., a Delaware corporation (“Payee”), at the address set forth in paragraph 9 below, the lesser of (i) the principal sum of Five Million Dollars ($5,000,000) (the “Maximum Amount”), or (ii) the unpaid pr |
|
| December 5, 2019 |
Exhibit 10.3 PROMISSORY NOTE $5,000,000 December 5, 2019 FOR VALUE RECEIVED, Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”) (“Maker”) promises to pay to the order of Cerecor Inc., a Delaware corporation (“Payee”), at the address set forth in paragraph 9 below, the lesser of (i) the principal sum of Five Million Dollars ($5,000,000) (the “Maximum Amount”), or (ii) the unpaid pr |
|
| November 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 20, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organi |
|
| November 20, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 18, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organi |
|
| November 20, 2019 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2019 |
Exhibit 10.1 Execution Copy CERTAIN INFORMATION IDENTIFIED WITH THE MARK “(***)”, “(***%***)” AND “(***$***)” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OPTION AND LICENSE AGREEMENT by and BETWEEN MEDIMMUNE LIMITED and AEVI GENOMIC MEDICINE, INC. TABLE OF CONTENTS ARTICLE 1 OPTION 1 1.1. Bindi |
|
| November 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Aevi Genomic Medicine, Inc. |
|
| November 14, 2019 |
Exhibit 10.2 435 Devon Park Drive, Suite 715 Wayne, PA 19087 t: 610 254 4201 f: 610 717 3390 aevigenomics.com November 11, 2019 Michael McInaw Dear Michael, I am writing to inform you that, in appreciation for your continued support of Aevi Genomic Medicine, Inc., the Company (“Aevi”) is offering you two retention bonuses. Aevi is offering these retention bonuses because it wants to reward you wit |
|
| October 22, 2019 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 9, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organiza |
|
| October 15, 2019 |
Exhibit 99.1 Aevi Genomic Medicine, Inc. Receives Positive Nasdaq Listing Determination October 15, 2019 - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, “the Company”) today announced that the Nasdaq Hearings Panel has agreed to the transfer of the Company’s shares to the Nasdaq Capital Market effective at the open of business on October 15, 2019 and granted the Company until February 3, 2020 to gain |
|
| October 4, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 4, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organiza |
|
| September 10, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 10, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organ |
|
| August 13, 2019 |
Exhibit 10.1 CERTAIN INFORMATION IDENTIFIED WITH THE MARK “(***)”, “(***%***)” AND “(***$***)” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Version EXCLUSIVE license AGREEMENT by and between OSI pharmaCEUTICALS, llc and Aevi Genomic Medicine, Inc. July 15, 2019 EXCLUSIVE LICENSE AGREEM |
|
| August 13, 2019 |
Exhibit 10.3 Execution Copy AMENDMENT NO. 3 TO LICENSE AGREEMENT This Amendment No. 3 to License Agreement (this “Amendment”) is entered into as of August 12, 2019 and is effective as of June 28, 2019 (the “Amendment Date”), by and between Medgenics Medical Israel Ltd. (“Licensee”), a company organized under the laws of the State of Israel and wholly owned subsidiary of Aevi Genomic Medicine, Inc. |
|
| August 13, 2019 |
Exhibit 10.2 CERTAIN INFORMATION IDENTIFIED WITH THE MARK “(***)” AND “(***%***)” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Version ROYALTY AGREEMENT This Royalty Agreement dated as of July 19, 2019 (as amended, supplemented or otherwise modified from time to time, this “Royalty Agr |
|
| August 13, 2019 |
Exhibit 10.4 Execution Copy AMENDMENT NO. 4 TO SPONSORED RESEARCH AGREEMENT This Amendment No. 4 to Sponsored research Agreement (this “Amendment”) is entered into as of August 12, 2019 and is effective as of June 28, 2019 (the “Amendment Date”), by and between Medgenics Medical Israel Ltd. (“Sponsor”), a company organized under the laws of the State of Israel and wholly owned subsidiary of Aevi G |
|
| August 13, 2019 |
GNMC / Aevi Genomic Medicine, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Aevi Genomic Medicine, Inc. |
|
| August 9, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organizat |
|
| August 7, 2019 |
© 2019, Aevi Genomic Medicine Company Overview Summer 2019 EX-99.2 3 tv526936ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 © 2019, Aevi Genomic Medicine Company Overview Summer 2019 © 2019, Aevi Genomic Medicine Confidential | 2 Forward - Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anti |
|
| August 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organizat |
|
| August 7, 2019 |
EX-99.1 2 tv526936ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Aevi Genomic Medicine Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody Plan to enter Phase 2 in Adult Onset Still’s Disease and other serious rare and orphan diseases August 7, 2019 - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, “Aevi”) today announced that it has obtained the right to exercise an exclusive global license f |
|
| August 6, 2019 |
GNMC / Aevi Genomic Medicine, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 6, 2019 |
GNMC / Aevi Genomic Medicine, Inc. PRER14A - - PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| July 26, 2019 |
GNMC / Aevi Genomic Medicine, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 19, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 19, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organizati |
|
| July 15, 2019 |
Exhibit 99.1 Press Release Aevi Genomic Medicine Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor Entering Phase 2 clinical trials for the treatment of Lymphatic Malformations which include a number of rare and orphan diseases. July 15, 2019 - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, “Aevi”) today announced it has ent |
|
| July 15, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 15, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organizati |
|
| June 24, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 20, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organizati |
|
| May 21, 2019 |
Letter Agreement, dated May 21, 2019, by and between Aevi Genomic Medicine, Inc. and Michael McInaw. Exhibit 10.1 435 Devon Park Drive, Suite 715 Wayne, PA 19087 t: 610 254 4201 f: 610 717 3390 aevigenomics.com May 21, 2019 Michael McInaw 3416 W. Queen Lane Philadelphia, PA 19129 Dear Mike, On behalf of Aevi Genomic Medicine, Inc. (“Aevi” or the “Company”), I am pleased to offer you the promotion to the position of Chief Financial Officer on an interim basis, reporting to me as CEO of Aevi. The e |
|
| May 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organizatio |
|
| May 14, 2019 |
Exhibit 10.2 Execution Version SECURITY AGREEMENT This SECURITY AGREEMENT (this “Agreement”) is dated as of March 29, 2019 and entered into by and Aevi Genomic Medicine, Inc., a Delaware corporation (“Aevi”), each of the undersigned direct and indirect Subsidiaries of Aevi (each of such undersigned Subsidiaries being a “Subsidiary Grantor” and, collectively, the “Subsidiary Grantors”) and each Add |
|
| May 14, 2019 |
Exhibit 10.6 Aevi Genomic Medicine, Inc. 435 Devon Park Drive, Suite 715 Wayne, Pennsylvania 19087 March 29, 2019 The Children's Hospital of Philadelphia 3401 Civic Center Blvd. Philadelphia, PA 19104 Attention: Tom Todorow, CFO Re: Agreement, dated March 25, 2019 Ladies and Gentlemen: This letter agreement (this “Agreement”) serves to formalize certain covenants made in the Agreement by and betwe |
|
| May 14, 2019 |
Exhibit 10.5 Execution Copy AMENDMENT NO. 3 TO SPONSORED RESEARCH AGREEMENT This Amendment No. 3 to Sponsored Research Agreement (this “Amendment”) is made and entered into as of March 29, 2019 (the “Amendment Date”), by and between Medgenics Medical Israel Ltd. (“Sponsor”) , a company organized under the laws of the State of Israel and wholly owned subsidiary of Aevi Genomic Medicine, Inc., a Del |
|
| May 14, 2019 |
Exhibit 10.3 Execution Copy AMENDMENT NO. 1 TO LICENSE AGREEMENT This Amendment No. 1 to License Agreement (this “Amendment”) is made and entered into as of March 29, 2019 (the “Amendment Date”), by and between Neurofix LLC (“Licensee”), a limited liability company and wholly owned subsidiary of Aevi Genomic Medicine, Inc. (“Aevi”), a Delaware corporation, and The Children’s Hospital of Philadelph |
|
| May 14, 2019 |
Exhibit 10.4 Execution Copy AMENDMENT NO. 2 TO LICENSE AGREEMENT This Amendment No. 2 to License Agreement (this “Amendment”) is made and entered into as of March 29, 2019 (the “Amendment Date”), by and between Medgenics Medical Israel Ltd. (“Licensee”) , a company organized under the laws of the State of Israel and wholly owned subsidiary of Aevi Genomic Medicine, Inc., a Delaware corporation (“A |
|
| May 14, 2019 |
Exhibit 10.1 Execution Version SECURED CONVERTIBLE PROMISSORY NOTE Date of Note: March 29, 2019 Principal Amount of Note: $3,166,666.64 For value received, Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”), promises to pay to the undersigned holder or such party’s assigns (the “Holder”) the principal amount set forth above. The outstanding principal amount of this secured convert |
|
| May 14, 2019 |
GNMC / Aevi Genomic Medicine, Inc. 10-Q Quarterly Report FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Aevi Genomic Medicine, Inc. |
|
| April 30, 2019 |
GNMC / Aevi Genomic Medicine, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| April 30, 2019 |
GNMC / Aevi Genomic Medicine, Inc. DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| April 8, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 2, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organizati |
|
| March 29, 2019 |
Subsidiaries of the Company (filed herewith). Exhibit 21.1 SUBSIDIARIES OF AEVI GENOMIC MEDICINE, INC. Medgenics Medical (Israel) Ltd., a company organized under the laws of the State of Israel neuroFix, LLC, a Delaware limited liability company Aevi Genomic Medicine Europe BVBA/SPRL, a company organized under the laws of Belgium |
|
| March 29, 2019 |
GNMC / Aevi Genomic Medicine, Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Aevi Genomic Medicine, Inc. |
|
| March 29, 2019 |
SC 13D/A 1 tv517556sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aevi Genomic Medicine, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 00835P105 (CUSIP Number) Jeffrey Kahn Executive Vice President and General Counsel The Children’s Hospital of Philadelphia |
|
| February 13, 2019 |
MDGN / Medgenics, Inc. / Baker Brothers Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tv511634sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aevi Genomic Medicine, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00835P105 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| February 12, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 6, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organiz |
|
| January 2, 2019 |
Exhibit 99.1 Aevi Genomic Medicine Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD PHILADELPHIA, January 2, 2019 /PRNewswire/ - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (“the Company”) today announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 ( |
|
| January 2, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 2, 2019 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organiza |
|
| November 1, 2018 |
GNMC / Aevi Genomic Medicine, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Aevi Genomic Medicine, Inc. |
|
| August 17, 2018 |
SC 13D/A 1 tv501255sc13da.htm SCHEDULE 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aevi Genomic Medicine, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 00835P105 (CUSIP Number) Jeffrey Kahn Executive Vice President and General Counsel The Children’s Hospital of Philade |
|
| August 14, 2018 |
Aevi Genomic Medicine Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD Exhibit 99.1 Aevi Genomic Medicine Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD · Top Line Data for Part A expected in Q4 2018 PHILADELPHIA, PA – (Marketwired) – August 14, 2018 – Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it has completed enrollment in Part A (n=64) of its Phase 2 ASCEND clinical trial, which is assessing a mGluR |
|
| August 14, 2018 |
Other Events, Financial Statements and Exhibits 8-K 1 tv5008688k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 14, 2018 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdictio |
|
| August 2, 2018 |
Exhibit 10.2 Amendment #2 to Sponsored Research Agreement This Amendment #2 to Sponsored Research Agreement (this “Amendment #2”), executed on November 12, 2014 (“Agreement”), is made and entered into as of February 16, 2017 (“Amendment #2 Effective Date”), by and between Medgenics Medical Israel, Ltd. (“SPONSOR”) and The Children’s Hospital of Philadelphia (“CHOP”). RECITALS Whereas SPONSOR and C |
|
| August 2, 2018 |
GNMC / Aevi Genomic Medicine, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Aevi Genomic Medicine, Inc. |
|
| July 11, 2018 |
GNMC / Aevi Genomic Medicine, Inc. S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 98-0217544 (I.R.S. Employer Identification Number) 435 Devon Park Drive, Suite 715, Wayne, PA 19087 (Address |
|
| June 22, 2018 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 18, 2018 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organizati |
|
| June 20, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 14, 2018 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organizati |
|
| May 23, 2018 |
GNMC / Aevi Genomic Medicine, Inc. CORRESP CORRESP 1 filename1.htm Aevi Genomic Medicine, Inc. 435 Devon Park Drive, Suite 715 Wayne, PA 19087 May 23, 2018 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street NE Washington, D.C. 20549 Attn: Dorrie Yale Re: Aevi Genomic Medicine, Inc. Registration Statement on Form S-3 Filed May 15, 2018 File No. 333-224929 Ladies an |
|
| May 15, 2018 |
Exhibit 1.1 Execution Version Aevi Genomic Medicine, Inc. Common Stock EQUITY DISTRIBUTION AGREEMENT Dated: May 15, 2018 TABLE OF CONTENTS SECTION 1. Description of Securities 1 SECTION 2. Placements 2 SECTION 3. Sale of Placement Securities by the Placement Agent 3 SECTION 4. Suspension of Sales 3 SECTION 5. Representations and Warranties 4 SECTION 6. Sale and Delivery to the Placement Agent; Set |
|
| May 15, 2018 |
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share data) Exhibit 99.1 Aevi Genomic Medicine Reports First Quarter 2018 Financial Results and Provides Business Update PHILADELPHIA, PA – (PRNewswire) – May 15, 2018 – Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the “Company”) announced today financial and operational results for the three months ended March 31, 2018 and provided an overview of the Company’s recent corporate progress. First Quarter Financia |
|
| May 15, 2018 |
8-K 1 tv4940538k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2018 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction o |
|
| May 15, 2018 |
GNMC / Aevi Genomic Medicine, Inc. FORM S-3 As filed with the Securities and Exchange Commission on May 15, 2018 securities and exchange commission Washington, D. |
|
| May 15, 2018 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) (To Prospectus dated April 1, 2016) Registration Statement No. |
|
| May 15, 2018 |
GNMC / Aevi Genomic Medicine, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use |
|
| May 15, 2018 |
GNMC / Aevi Genomic Medicine, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Aevi Genomic Medicine, Inc. |
|
| May 15, 2018 |
Exhibit 10.1 ***FORM*** AEVI GENOMIC MEDICINE, INC. Stock Incentive Plan Non-Qualified Stock Option Award Terms The Participant specified below has been granted this Non-Qualified Option (the “Option”) by Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”), under the terms of the Aevi Genomic Medicine, Inc. Stock Incentive Plan, as amended from time to time (the “Incentive Plan”). |
|
| April 30, 2018 |
GNMC / Aevi Genomic Medicine, Inc. DEFR14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| April 27, 2018 |
GNMC / Aevi Genomic Medicine, Inc. DEFA14A DEFA14A 1 tv492023defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ C |
|
| April 27, 2018 |
GNMC / Aevi Genomic Medicine, Inc. DEF 14A DEF 14A 1 tv491837def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 21, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 19, 2018 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organizat |
|
| March 13, 2018 |
Exhibit 99.2 © 2018, Aevi Genomic Medicine NASDAQ: GNMX 2017 Year - end Results and Corporate Update March 13, 2018 © 2018, Aevi Genomic Medicine 2 Forward - Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anticipated opera |
|
| March 13, 2018 |
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share data) Exhibit 99.1 Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update PHILADELPHIA, PA – (PRNewswire) – March 13, 2018 – Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today financial and operational results for the three and twelve months ended December 31, 2017. Fourth Quarter and Year-End Corporate Highlights · Continued |
|
| March 13, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 13, 2018 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organizat |
|
| March 13, 2018 |
Subsidiaries of the Company (filed herewith). Exhibit 21.1 SUBSIDIARIES OF AEVI GENOMIC MEDICINE, INC. Medgenics Medical (Israel) Ltd., a company organized under the laws of the State of Israel neuroFix, LLC, a Delaware limited liability company. |
|
| March 13, 2018 |
GNMX / Aevi Genomic Medicine, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Aevi Genomic Medicine, Inc. |
|
| March 6, 2018 |
8-K 1 tv4878728k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2018 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdicti |
|
| February 13, 2018 |
MDGN / Medgenics, Inc. / Baker Brothers Advisors LP - SCHEDULE 13G Passive Investment SC 13G 1 tv485137sc13g.htm SCHEDULE 13G SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. )* Aevi Genomic Medicine, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00835P105 (CUSIP number) December 31, 2017 (Date of event which requires filing of this statement) Check the appr |
|
| February 13, 2018 |
MDGN / Medgenics, Inc. / Broadfin Capital, LLC Passive Investment SC 13G/A 1 d780861113g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Aevi Genomic Medicine, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 00835P105 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 13, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aevi Genomic Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00835P105 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 13, 2018 |
EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Aevi Genomic Medicine, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 13, 2018 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC |
|
| February 6, 2018 |
MDGN / Medgenics, Inc. / HARPER PHILIP R - AMENDMENT TO FORM SC 13G Passive Investment SC 13G/A 1 harper-sc13ga020118.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) AEVI GENOMIC MEDICINE, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 00835P105 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of thi |
|
| January 5, 2018 |
AEVI GENOMIC MEDICINE, INC. 26,176,126 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-221950 PROSPECTUS AEVI GENOMIC MEDICINE, INC. 26,176,126 Shares of Common Stock This prospectus relates to the resale of up to 26,176,126 shares of common stock, par value $0.0001 per share, of Aevi Genomic Medicine, Inc., by the selling stockholders identified beginning on page 8 of this prospectus, together with any additional selling stockho |
|
| January 2, 2018 |
GNMX / Aevi Genomic Medicine, Inc. ESP CORRESP 1 filename1.htm Aevi Genomic Medicine, Inc. 435 Devon Park Drive, Suite 715 Wayne, PA 19087 January 2, 2018 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street NE Washington, D.C. 20549 Attn: Ms. Ada D. Sarmento Re: Aevi Genomic Medicine, Inc. Registration Statement on Form S-3 Filed December 8, 2017 File No. 333-2 |
|
| December 28, 2017 |
GNMX / Aevi Genomic Medicine, Inc. S-3/A As filed with the Securities and Exchange Commission on December 28, 2017 SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 28, 2017 |
GNMX / Aevi Genomic Medicine, Inc. ESP CORRESP 1 filename1.htm 3000 Two Logan Square Eighteenth and Arch Streets Philadelphia, PA 19103-2799 215.981.4000 Brian M. Katz direct dial: 215.981.4193 [email protected] December 28, 2017 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street NE Washington, D.C. 20549 Attn: Ms. Ada D. Sarmento Re: Aevi Genomic Medicine, |
|
| December 8, 2017 |
As filed with the Securities and Exchange Commission on December 8, 2017 SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 4, 2017 |
Exhibit 24 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of Brian Piper and Bill Noss with full power to act singly as the undersigned?s true and lawful attorneys-in-fact, with full power of substitution, to: 1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director and/or beneficial owner of Aevi Genomic Medicine, Inc. |
|
| December 4, 2017 |
8-K 1 tv4807368k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 4, 2017 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of |
|
| December 4, 2017 |
Exhibit 10.1 INDEMNIfication AGREEMENT This Indemnification Agreement (?Agreement?) is made as of December , 2017, by and between Aevi Genomic Medicine, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS WHEREAS, the board of directors of the Company (the ?Board?) has determined that enhancing the ability of the Company to retain and attract as directors and officers the mo |
|
| December 4, 2017 |
Aevi Genomic Medicine Announces New Appointment to its Board of Directors Exhibit 99.1 Aevi Genomic Medicine Announces New Appointment to its Board of Directors PHILADELPHIA, PA ? (PR Newswire) ? 12/4/17 ? Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today the appointment of Matthew D. Bayley, MD, MBA to its Board of Directors. "We are excited to welcome Matt to our Board of Directors during this important time for the Company?, said Mike Cola, CEO |
|
| November 13, 2017 |
Amendment No. 2 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Aevi Genomic Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00835P 10 5 (CUSIP Number) Isaac Blech 1271 Avenue of the Americas, 16th Floor New York, NY 10020 (Name, Address and Telep |
|
| November 2, 2017 |
GNMX / Aevi Genomic Medicine, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Aevi Genomic Medicine, Inc. |
|
| October 18, 2017 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AEVI GENOMIC MEDICINE, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Aevi Genomic Medicine, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify: 1. The name of the corporat |
|
| October 18, 2017 |
Aevi Genomic Medicine Announces Completion of $28 Million Private Placement Exhibit 99.1 Aevi Genomic Medicine Announces Completion of $28 Million Private Placement PHILADELPHIA, Oct. 17, 2017 /PRNewswire/ - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX)(the "Company") today announced the completion of a previously announced private placement of 22.2 million shares of its common stock with warrants to purchase approximately 4.0 million additional shares of its common stock, f |
|
| October 18, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 17, 2017 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organiz |
|
| October 17, 2017 |
MDGN / Medgenics, Inc. / Children's Hospital of Philadelphia Foundation - SC 13D Activist Investment SC 13D 1 tv476729sc13d.htm SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Aevi Genomic Medicine, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 00835P105 (CUSIP Number) Jeffrey Kahn Executive Vice President and General Counsel The Children’s Hospital of Philadelphia Founda |
|
| September 8, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| August 28, 2017 |
PRE 14A 1 v474100pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| August 15, 2017 |
8-K 1 v4733848k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 11, 2017 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of i |
|
| August 11, 2017 |
FORM OF REGISTRATION RIGHTS AGREEMENT Exhibit 10.2 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of [], 2017 by and among Aevi Genomic Medicine, Inc., a Delaware corporation (the ?Company?), and the several purchasers signatory hereto (each a ?Purchaser? and collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Purchase Agreement, da |
|
| August 11, 2017 |
FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of [], 2017 by and among Aevi Genomic Medicine, Inc., a Delaware corporation (the ?Company?), and each purchaser listed on Schedule A attached hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). RECITALS A. The Company and each Purc |
|
| August 11, 2017 |
Exhibit 4.1 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIE |
|
| August 11, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2017 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organizat |
|
| August 10, 2017 |
Regulation FD Disclosure, Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v4727748k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2017 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction |
|
| August 10, 2017 |
HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine NASDAQ: GNMX Corporate Update August 10, 2017 Exhibit 99.2 HIGHLY CONFIDENTIAL ? 2017, Aevi Genomic Medicine NASDAQ: GNMX Corporate Update August 10, 2017 HIGHLY CONFIDENTIAL ? 2017, Aevi Genomic Medicine 2 Forward - Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anti |
|
| August 10, 2017 |
Exhibit 99.1 Aevi Genomic Medicine Announces Agreement for $28 Million Private Placement PHILADELPHIA, PA ? (Marketwired) ? 08/10/17 ? Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the ?Company?) today announced the execution of a definitive agreement to sell shares of common stock and warrants to purchase common stock in a private placement, or PIPE, to certain accredited investors, led by Children |
|
| August 9, 2017 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 v4727758k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2017 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction |
|
| August 9, 2017 |
Aevi Genomic Medicine Reports Second Quarter 2017 Financial Results Exhibit 99.1 Aevi Genomic Medicine Reports Second Quarter 2017 Financial Results PHILADELPHIA, PA ? (Marketwired) ? 08/09/17 ? Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today financial and operational results for the quarter ended June 30, 2017 and provided a corporate update. Second Quarter Corporate Highlights ? Initiating Phase 2 clinical trial in contactin-4 mutation-p |
|
| August 9, 2017 |
GNMX / Aevi Genomic Medicine, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Aevi Genomic Medicine, Inc. |
|
| August 8, 2017 |
MEDGENICS, INC. Non-Qualified Stock Option Award Terms Exhibit 99.2 MEDGENICS, INC. Non-Qualified Stock Option Award Terms Pursuant to the employment inducement grant exception to the shareholder approval requirements contained in Section 711 of the NYSE MKT Rules, the Participant specified below has been granted an Option by Medgenics, inc., a Delaware corporation (the ?Company?), it being understood that such grant has not been made pursuant to the |
|
| August 8, 2017 |
Aevi Genomic Medicine FORM S-8 As filed with the Securities and Exchange Commission on August 8, 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 8, 2017 |
MEDGENICS, INC. Non-Qualified Stock Option Award Terms Exhibit 99.1 MEDGENICS, INC. Non-Qualified Stock Option Award Terms Pursuant to the employment inducement grant exception to the shareholder approval requirements contained in Section 711 of the NYSE MKT Rules, the Participant specified below has been granted an Option by Medgenics, Inc., a Delaware corporation (the ?Company?), it being understood that such grant has not been made pursuant to the |
|
| June 30, 2017 |
8-K 1 v4700928-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2017 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction |
|
| June 19, 2017 |
8-K 1 v4691388k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 19, 2017 (June 14, 2017) Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jur |
|
| June 2, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aevi Genomic Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00835P105 (CUSIP Number) May 24, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| May 10, 2017 |
Exhibit 99.1 Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 and First Quarter 2017 Operating Results ? Company to initiate a Phase 2 clinical trial in 2H 2017, targeting a specific genetic subset of patients identified by a responder analysis of the SAGA trial ? Responder subset is approximately 10% of the US pediatric ADHD popula |
|
| May 10, 2017 |
© 2017, Aevi Genomic Medicine NASDAQ: GNMX Corporate Update May 10, 2017 Exhibit 99.2 ? 2017, Aevi Genomic Medicine NASDAQ: GNMX Corporate Update May 10, 2017 ? 2017, Aevi Genomic Medicine 2 Forward - Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anticipated operating and financial performance |
|
| May 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2017 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organizatio |
|
| May 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Aevi Genomic Medicine, Inc. |
|
| May 10, 2017 |
Exhibit 10.2 Amendment #2 to Sponsored Research Agreement This Amendment #2 to Sponsored Research Agreement (this “Amendment #2”), executed on November 12, 2014 (“Agreement”), is made and entered into as of November 30, 2016 (“Amendment #2 Effective Date”) by and between Medgenics Medical Israel, Ltd. (“SPONSOR”) and The Children’s Hospital of Philadelphia (“CHOP”). RECITALS Whereas SPONSOR and CH |
|
| May 10, 2017 |
Exhibit 10.1 *** Confidential Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to this omitted information. AMENDMENT NO. 1 TO LICENSE AGREEMENT This Amendment No. 1 to License Agreement (this “Amendment”) is made and entered into as of the 14th day of February 2017 (the “Amendment Effective Date”) |
|
| May 1, 2017 |
DEF 14A 1 v465303def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 25, 2017 |
8-K 1 v4650028k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 24, 2017 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction |
|
| March 30, 2017 |
MDGN / Medgenics, Inc. / HARPER PHILIP R - ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment SC 13G 1 harper-sc13g032017.htm ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* AEVI GENOMIC MEDICINE, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 00835P105 (CUSIP Number) March 20, 2017 (Date of Event Which Requires Filing of this Statement) |
|
| March 20, 2017 |
© 2017, Aevi Genomic Medicine AEVI - 001: SAGA Trial in mGluR + ADHD Topline Results March 20, 2017 Exhibit 99.2 ? 2017, Aevi Genomic Medicine AEVI - 001: SAGA Trial in mGluR + ADHD Topline Results March 20, 2017 ? 2017, Aevi Genomic Medicine 2 Forward - Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anticipated operatin |
|
| March 20, 2017 |
Exhibit 99.1 Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001 ? Trial did not meet primary endpoint (overall ADHD-RS), however showed encouraging trend in improvement at highest dose (400 mg BID) Strong trend of efficacy in ADHD-RS inattention subscale (p=0.0515 vs placebo) ? Clear signal of efficacy and benefit to patients ADHD-RS response rate 70% (p=0.0067 vs plac |
|
| March 20, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v4621898-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 20, 2017 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction |
|
| March 9, 2017 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 v4614548k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 9, 2017 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of inc |
|
| March 9, 2017 |
Exhibit 99.1 Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update Top-line data from SAGA Phase 2/3 trial of AEVI-001 in adolescents with mGluR+ ADHD to be announced by end of Q1 Robust pipeline with data from several AEVI-001 signal finding studies expected in 2017 PHILADELPHIA, PA ? (Marketwired) ? 03/09/17 ? Aevi Genomic Medicine, Inc. ( |
|
| March 9, 2017 |
SUBSIDIARIES OF AEVI GENOMIC MEDICINE, INC. Exhibit 21.1 SUBSIDIARIES OF AEVI GENOMIC MEDICINE, INC. Medgenics Medical (Israel) Ltd., a company organized under the laws of the State of Israel neuroFix, LLC, a Delaware limited liability company |
|
| March 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Aevi Genomic Medicine, Inc. |
|
| February 27, 2017 |
8-K 1 v4601168-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 27, 2017 (February 21, 2017) Aevi Genomic Medicine, Inc. (Exact Name of Issuer as Specified in Charter) Delaware (State or Other Jurisdiction of |
|
| February 27, 2017 |
EX-99.1 2 v460116ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Aevi Genomic Medicine Announces Expansion of its Collaboration with The Children’s Hospital of Philadelphia PHILADELPHIA, PA – (Marketwired) – 02/21/2017 – Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that it has strengthened its discovery and research platform by extending |
|
| February 23, 2017 |
GNMX / Aevi Genomic Medicine, Inc. / Opaleye Management Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Aevi Genomic Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 58436Q203 (CUSIP Number) Opaleye Management Inc., One Boston Place, Suite 2600, Boston, MA 02108, 617-229-5085 (Name, Address and Telephone Number |
|
| February 13, 2017 |
MDGN / Medgenics, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 6, 2017 |
MDGN / Medgenics, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 15, 2016 |
Medgenics, Inc. Announces Name Change to Aevi Genomic Medicine, Inc. Exhibit 99.1 NEWS RELEASE Medgenics, Inc. Announces Name Change to Aevi Genomic Medicine, Inc. PHILADELPHIA, PA, December 15, 2016 - Medgenics, Inc. (NASDAQ: MDGN) today announced that the company has changed its name to Aevi Genomic Medicine, Inc. Aevi Genomic Medicine (pronounced ?AHH-vee?) is a name inspired by the Old Norse language which means ?life story? and reflects the Company?s mission o |
|
| December 15, 2016 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MEDGENICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Medgenics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify: 1. The name of the corporation is Medgenics, Inc. 2 |
|
| December 15, 2016 |
Exhibit 3.2 Third Amended and Restated By-Laws of Aevi Genomic Medicine, Inc. Incorporated under the Laws of the State of Delaware Adopted as of December 15, 2016 BY-LAWS OF AEVI GENOMIC MEDICINE, INC. (a Delaware Corporation) ARTICLE I: OFFICES Section 1. Registered Office. The registered office of the Corporation in the state of Delaware shall be located at 1013 Centre Road, New Castle County, i |
|
| December 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 15, 2016 Date of Report (Date of earliest event reported) AEVI GENOMIC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organi |
|
| November 3, 2016 |
Exhibit 99.1 NEWS RELEASE Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder PHILADELPHIA, PA, October 29, 2016 – Medgenics, Inc. (NASDAQ: MDGN)– New data presented at AACAP’s 63rd Annual Meeting (Oct. 24-29, 2016 in New York, NY) confirmed the presence of specific genetic mutations in many children with Attent |
|
| November 3, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v4520008-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 29, 2016 Date of Report (Date of earliest event reported) MEDGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorp |
|
| November 3, 2016 |
Medgenics Reports Third Quarter 2016 Financial Results Exhibit 99.1 News Release Medgenics Reports Third Quarter 2016 Financial Results PHILADELPHIA, PA ? (Marketwired) ? November 3, 2016 - Medgenics, Inc. (NASDAQ: MDGN) ? Presented Data Confirming Prevalence of Genetic Mutations in Pediatric ADHD at the 63rd Annual American Academy of Child and Adolescent Psychiatry (AACAP) Meeting ? Began Trading on the NASDAQ Global Markets Medgenics, Inc. (NASDAQ: |
|
| November 3, 2016 |
8-K 1 v4520018-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2016 Date of Report (Date of earliest event reported) MEDGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorp |
|
| November 3, 2016 |
Q3 Business Update and Financials November 3, 2016 Exhibit 99.2 Q3 Business Update and Financials November 3, 2016 Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anticipated operating and financial performance, clinical results, potential partnerships, licensing op |
|
| November 3, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Medgenics, Inc. |
|
| October 20, 2016 |
25 1 v450784form25.htm 25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 1-35112 Medgenics, Inc. – NYSE MKT LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered |
|
| October 20, 2016 |
8-A12B 1 v4507858a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Medgenics, Inc. (Exact name of registrant as specified in its charter) Delaware 99-0217544 (State or other jurisdiction of incorporation or organization) (IRS Emplo |
|
| October 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 10, 2016 Medgenics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 1-35112 (Commission File Nu |
|
| October 11, 2016 |
Medgenics, Inc. to Begin Trading on Nasdaq Global Market Exhibit 99.1 NEWS RELEASE Medgenics, Inc. to Begin Trading on Nasdaq Global Market PHILADELPHIA, PA, October 10, 2016 – Medgenics, Inc. (NYSE Amex: MDGN) (the “Company”) announced today that it has been approved for listing on the NASDAQ Global Market, continuing to trade under the symbol “MDGN.” Trading on the NASDAQ Global Market is expected to commence on October 21, 2016. The Company’s common |
|
| August 4, 2016 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 v4458328-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 4, 2016 Medgenics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) |
|
| August 4, 2016 |
Exhibit 16.1 August 4, 2016 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Commissioners: We have read the statements of Medgenics, Inc. included under Item 4.01 of its Form 8-K filed on August 4, 2016, and we agree with such statements concerning our firm. We have no basis to agree or disagree with other statements of the registrant contained therein. /s/ Kost Forer |
|
| August 4, 2016 |
Mid - Year Review and Business Update August 4, 2016 Exhibit 99.2 Mid - Year Review and Business Update August 4, 2016 Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anticipated operating and financial performance, clinical results, potential partnerships, licensing |
|
| August 4, 2016 |
Medgenics Reports Second Quarter 2016 Financial Results Exhibit 99.1 News Release Medgenics Reports Second Quarter 2016 Financial Results PHILADELPHIA, PA ? (Marketwired) ? August 4, 2016 - Medgenics, Inc. (NYSE MKT: MDGN) ? Initiated Phase 2/3 study of lead program in mGluR+ ADHD ? Entered into collaboration for second pediatric product in Inflammatory Bowel Disease ? Strengthened balance sheet with successful financing Medgenics, Inc. (NYSE MKT: MDGN |
|
| August 4, 2016 |
8-K 1 v4458918k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 4, 2016 Date of Report (Date of earliest event reported) MEDGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorpora |
|
| August 4, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Medgenics, Inc. |
|
| August 4, 2016 |
EX-10.1 2 v444666ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version Portions of this exhibit have been omitted and filed separately with the Secretary of the Securities and Exchange Commission (the “Commission”) pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. Such portions are marked a |
|
| June 30, 2016 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Medgenics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 58436Q203 (CUSIP Number) June 21, 2016 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| June 29, 2016 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The NYSE MKT LLC hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on July 11, 2016, pursuant to the provisions of Rule 12d2-2 (a). |
|
| June 24, 2016 |
Medgenics Announces Public Offering of Common Stock Exhibit 99.1 NEWS RELEASE Medgenics Announces Public Offering of Common Stock PHILADELPHIA, PA – (Marketwired) – June 20, 2016 — Medgenics, Inc. (NYSE: MDGN), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. All of the shares to be sold in t |
|
| June 24, 2016 |
Medgenics Announces Pricing of Public Offering of Common Stock Exhibit 99.2 NEWS RELEASE Medgenics Announces Pricing of Public Offering of Common Stock PHILADELPHIA, PA ? (Marketwired) - June 21, 2016 ? Medgenics, Inc. (NYSE MKT:MDGN) today announced the pricing of 3,640,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $5.50 per share. In connection with the offering, Medgenics has also granted |
|
| June 24, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 21, 2016 Medgenics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 1-35112 (Commission File Numbe |
|
| June 24, 2016 |
Exhibit 1.1 3,640,000 Shares MEDGENICS, INC. Common Stock PURCHASE AGREEMENT June 21, 2016 JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Medgenics, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) for whom Jeffer |
|
| June 22, 2016 |
424B5 1 v442723424b5.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-209737 Prospectus Supplement (To Prospectus dated April 1, 2016) 3,640,000 Shares Common Stock We are offering 3,640,000 shares of our common stock. Our common stock is listed on the NYSE MKT under the symbol “MDGN.” On June 20, 2016, the last reported sale price of our common stock on the NYSE MKT was $6.24 per s |
|
| June 20, 2016 |
The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| June 17, 2016 |
Exhibit 99.1 News Release Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents with mGluR Mutation Positive ADHD PHILADELPHIA, PA ? (Marketwired) ? June 17, 2016 - Medgenics, Inc. (NYSE: MDGN) today announced the enrollment of the first patient into the SAGA (Study of Adolescent Glutamate Receptor Network Copy Number Variant ADHD) trial - a Phase 2/3 |
|
| June 17, 2016 |
8-K 1 v4424658k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 16, 2016 Medgenics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 1-3511 |
|
| June 6, 2016 |
Exhibit 99.2 Medgenics / Kyowa Hakko Kirin Collaboration for Severe Pediatric Onset Inflammatory Bowel Disease June 6, 2016 Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, including statements with respect to anticipated operating and financial perfo |
|
| June 6, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v4417258k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 6, 2016 Medgenics, Inc. (Exact Name of Issuer as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 1-35112 (Co |
|
| June 6, 2016 |
Medgenics Obtains Rights to First-in-Class Biologic for Severe Pediatric Onset IBD Exhibit 99.1 News Release Medgenics Obtains Rights to First-in-Class Biologic for Severe Pediatric Onset IBD ? Collaboration with Kyowa Hakko Kirin to develop anti-LIGHT monoclonal antibody ? Second program from research collaboration with The Children?s Hospital of Philadelphia (CHOP) Center for Applied Genomics (CAG) ? Data from signal finding study in Severe Pediatric Onset Inflammatory Bowel D |
|
| May 10, 2016 |
Q1 2016 Results and NFC - 1 Program Update May 10, 2016 Exhibit 99.2 Q1 2016 Results and NFC - 1 Program Update May 10, 2016 Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, including statements with respect to anticipated operating and financial performance, clinical results, potential partnerships, licen |
|
| May 10, 2016 |
8-K 1 v4393578k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2016 Date of Report (Date of earliest event reported) MEDGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or |
|
| May 10, 2016 |
Medgenics Reports First Quarter 2016 Financial Results and NFC-1 Program Update EX-99.1 2 v439357ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 News Release Medgenics Reports First Quarter 2016 Financial Results and NFC-1 Program Update · Rapid enrollment in phenotype/genotype study of mGluR positive ADHD patients · Data support the prevalence of mGluR mutation in broad ADHD population · Enrollment to begin in Phase 2/3 clinical trial in mGluR+ ADHD patients · Enrollment to begin in Ph |
|
| May 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Medgenics, Inc. |
|
| April 14, 2016 |
MEDGENICS, INC. Non-Qualified Stock Option Award Terms Exhibit 99.5 MEDGENICS, INC. Non-Qualified Stock Option Award Terms Pursuant to the employment inducement grant exception to the shareholder approval requirements contained in Section 711 of the NYSE MKT Rules, the Participant specified below has been granted an Option by Medgenics, Inc., a Delaware corporation (the “Company”), it being understood that such grant has not been made pursuant to the |
|
| April 14, 2016 |
MEDGENICS, INC. Non-Qualified Stock Option Award Terms Exhibit 99.4 MEDGENICS, INC. Non-Qualified Stock Option Award Terms Pursuant to the employment inducement grant exception to the shareholder approval requirements contained in Section 711 of the NYSE MKT Rules, the Participant specified below has been granted an Option by Medgenics, Inc., a Delaware corporation (the “Company”), it being understood that such grant has not been made pursuant to the |
|
| April 14, 2016 |
MEDGENICS, INC. Non-Qualified Stock Option Award Terms Exhibit 99.3 MEDGENICS, INC. Non-Qualified Stock Option Award Terms Pursuant to the employment inducement grant exception to the shareholder approval requirements contained in Section 711 of the NYSE MKT Rules, the Participant specified below has been granted an Option by Medgenics, Inc., a Delaware corporation (the “Company”), it being understood that such grant has not been made pursuant to the |
|
| April 14, 2016 |
MEDGENICS, INC. Non-Qualified Stock Option Award Terms EX-99.1 4 v436827ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 MEDGENICS, INC. Non-Qualified Stock Option Award Terms Pursuant to the employment inducement grant exception to the shareholder approval requirements contained in Section 711 of the NYSE MKT Rules, the Participant specified below has been granted an Option by Medgenics, Inc., a Delaware corporation (the “Company”), it being understood that such |
|
| April 14, 2016 |
MEDGENICS, INC. Non-Qualified Stock Option Award Terms Exhibit 99.2 MEDGENICS, INC. Non-Qualified Stock Option Award Terms Pursuant to the employment inducement grant exception to the shareholder approval requirements contained in Section 711 of the NYSE MKT Rules, the Participant specified below has been granted an Option by Medgenics, Inc., a Delaware corporation (the “Company”), it being understood that such grant has not been made pursuant to the |
|
| April 14, 2016 |
As filed with the Securities and Exchange Commission on April 14, 2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 13, 2016 |
Exhibit 10.1 THIRD AMENDMENT OF THE MEDGENICS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED EFFECTIVE MARCH 5, 2012) WHEREAS, Medgenics, Inc. (the ?Company?) maintains the Medgenics, Inc. Stock Incentive Plan (As Amended and Restated Effective March 5, 2012), as amended by the First Amendment thereto effective as of April 30, 2013 and the Second Amendment thereto effective as of April 8, 201 |
|
| April 13, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 13, 2016 (April 12, 2016) Date of Report (Date of earliest event reported) MEDGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or orga |
|
| March 30, 2016 |
CORRESP 1 filename1.htm Medgenics, Inc. 435 Devon Park Drive, Building 700 Wayne, PA 19087 March 30, 2016 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Medgenics, Inc. Registration Statement on Form S-3 Filed February 26, 2016 (File No. 333-209737) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), |
|
| March 11, 2016 |
Medgenics DEFINITIVE PROXY STATEMENT DEF 14A 1 mdgn-def14a041216.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| February 26, 2016 |
MEDGENICS, INC. , as Trustee Dated as of , TABLE OF CONTENTS EX-4.9 2 v432709ex4-9.htm EXHIBIT 4.9 Exhibit 4.9 MEDGENICS, INC. and , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS 1 1.2. OTHER DEFINITIONS 5 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 6 1.4. RULES OF CONSTRUCTION 6 ARTICLE 2 THE SECURITIES 7 2.1. ISSUABLE IN SERIES 7 2.2. ESTABLISHMENT OF TERMS OF S |
|
| February 26, 2016 |
As filed with the Securities and Exchange Commission on February 26, 2016 securities and exchange commission Washington, D. |
|
| February 26, 2016 |
SUBSIDIARIES OF MEDGENICS, INC. Exhibit 21.1 SUBSIDIARIES OF MEDGENICS, INC. Medgenics Medical (Israel) Ltd., a company organized under the laws of the State of Israel neuroFix, LLC, a Delaware limited liability company |
|
| February 26, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35112 Medgenics, Inc. |
|
| February 18, 2016 |
POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Scott Applebaum, and with full powers and substitution, the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U. |
|
| February 17, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 17, 2016 Date of Report (Date of earliest event reported) MEDGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 1-35112 98-0217544 (State or other jurisdiction of incorporation or organization) (Com |
|
| February 17, 2016 |
2015 Year End Results and Operations Update February 17, 2016 Exhibit 99.2 2015 Year End Results and Operations Update February 17, 2016 Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, including statements with respect to anticipated operating and financial performance, clinical results, potential partnerships, |
|
| February 17, 2016 |
Exhibit 99.1 Medgenics Reports Fourth Quarter and Full Year 2015 Results and Advancement of NFC-1 Development Programs ? Enrollment Initiated in Groundbreaking Non-interventional Phenotype/Genotype Study of mGluR Mutations in ADHD ? IND Clearance Received for 22Q11.2 Deletion Syndrome PHILADELPHIA, PA ? (Marketwired) ? 02/17/16 ? Medgenics, Inc. (NYSE MKT: MDGN) today reported financial results fo |
|
| February 12, 2016 |
GNMX / Aevi Genomic Medicine, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
